// App-Quantinova.ai

AB0659 : SECUKINUMAB PROVIDES SIGNIFICANT IMPROVEMENT OF SPINAL PAIN IN PATIENTS WITH AXIAL SPONDYLOARTHRITIS: RESULTS FROM THE 24-WEEK PHASE 3 SKIPPAIN STUDY

Researchers

Presenter

  • D. Poddubnyy

Principal Investigators

  • E. Pournara

  • A. Zielinska

  • A. Baranauskaite

  • A. Muoz Jimenez

  • P. Kumari

  • B. Schulz

  • M. Rissler

  • C. Perella

  • H. Marzo-Ortega

Medical Centers

  • Charite Univsmedizin Berlin, Berlin, Germany

  • Novartis AG, Basel, Switzerland

  • Medycyna Kliniczna, Warszawa, Poland

  • Lithuanian University of Health Sciences, Kaunas, Lithuania

  • HU Virgen del Rocio/IBIS, Sevilla, Spain

  • Novartis Healthcare Pvt. Ltd, Hyderabad, India

  • NIHR Leeds Biomedical Research Centre, LTHT and LIRMM, University of Leeds, Leeds, United Kingdom

Locations

  • Germany

  • Switzerland

  • Poland

  • Lithuania

  • Spain

  • India

  • United Kingdom

Companies

  • Novartis AG

Study Components

Therapeutic Area

  • Musculoskeletal

  • Autoimmune (AI)

Disease

  • Axial spondyloarthritis

  • Ankylosing spondylitis

  • Spondyloarthritis

Biomarkers

  • Nutritional risk screening

Drug/Treatment

  • secukinumab

Outcome

  • N/A

Study Design

  • Randomized

  • Double Blind/Blinded

  • Superiority

  • Multicenteric

  • Controlled

Phase

  • III

Study Id's

  • NCT03136861

Sponsors

  • Abbvie

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved